GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Cyclically Adjusted Price-to-FCF

BB Biotech AG (XSWX:BION) Cyclically Adjusted Price-to-FCF : 18.06 (As of Apr. 30, 2024)


View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG Cyclically Adjusted Price-to-FCF?

As of today (2024-04-30), BB Biotech AG's current share price is CHF41.35. BB Biotech AG's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was CHF2.29. BB Biotech AG's Cyclically Adjusted Price-to-FCF for today is 18.06.

The historical rank and industry rank for BB Biotech AG's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

XSWX:BION' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 17.06   Med: 18.67   Max: 22.52
Current: 18.64

During the past years, BB Biotech AG's highest Cyclically Adjusted Price-to-FCF was 22.52. The lowest was 17.06. And the median was 18.67.

XSWX:BION's Cyclically Adjusted Price-to-FCF is ranked better than
87.25% of 102 companies
in the Biotechnology industry
Industry Median: 54.05 vs XSWX:BION: 18.64

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

BB Biotech AG's adjusted free cash flow per share data for the three months ended in Dec. 2023 was CHF-0.017. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is CHF2.29 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


BB Biotech AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BB Biotech AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Cyclically Adjusted Price-to-FCF Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 22.51 18.64

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.51 18.12 18.51 18.18 18.64

Competitive Comparison of BB Biotech AG's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BB Biotech AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Cyclically Adjusted Price-to-FCF falls into.



BB Biotech AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BB Biotech AG's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=41.35/2.29
=18.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, BB Biotech AG's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.017/106.4611*106.4611
=-0.017

Current CPI (Dec. 2023) = 106.4611.

BB Biotech AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201106 0.000 102.678 0.000
201109 0.960 101.811 1.004
201112 0.356 101.408 0.374
201203 1.550 101.826 1.621
201206 -0.127 101.596 -0.133
201209 2.377 101.392 2.496
201212 0.357 100.968 0.376
201303 0.996 101.221 1.048
201306 1.845 101.466 1.936
201309 -0.592 101.336 -0.622
201312 1.270 101.036 1.338
201403 -0.204 101.224 -0.215
201406 0.058 101.517 0.061
201409 0.404 101.247 0.425
201412 1.897 100.704 2.005
201503 3.144 100.339 3.336
201506 2.678 100.464 2.838
201509 -3.412 99.785 -3.640
201512 -1.515 99.386 -1.623
201603 -0.386 99.475 -0.413
201606 0.263 100.088 0.280
201609 2.219 99.604 2.372
201612 0.015 99.380 0.016
201703 0.946 100.040 1.007
201706 5.782 100.285 6.138
201712 0.000 100.213 0.000
201812 0.000 100.906 0.000
201912 0.000 101.063 0.000
202012 0.000 100.241 0.000
202103 -1.806 100.800 -1.907
202106 0.908 101.352 0.954
202112 0.000 101.776 0.000
202203 4.003 103.205 4.129
202206 0.678 104.783 0.689
202209 0.601 104.835 0.610
202212 -1.099 104.666 -1.118
202303 3.704 106.245 3.712
202306 0.155 106.576 0.155
202309 0.136 106.570 0.136
202312 -0.017 106.461 -0.017

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BB Biotech AG  (XSWX:BION) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BB Biotech AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (XSWX:BION) Business Description

Industry
Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Executives
Prof. Dr. Mads Krogsgaard Thomsen Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines